Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3009 Target Snapshot

Receptor tyrosine-protein kinase erbB-4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,113Compounds
532Assays
32Approved Drugs
1,159.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Receptor tyrosine-protein kinase erbB-4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q15303. Start with neoplasm, then reuse UniProt Q15303 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt Q15303 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
neoplasm

Receptor tyrosine-protein kinase erbB-4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AC-480, BMS-690514, DACOMITINIB, DACOMITINIB ANHYDROUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor tyrosine-protein kinase erbB-4 as ChEMBL target CHEMBL3009, mapped to UniProt Q15303. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Receptor tyrosine-protein kinase erbB-4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3009
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q15303
Receptor tyrosine-protein kinase erbB-4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Receptor tyrosine-protein kinase erbB-4 is the right protein anchor across sources, using UniProt Q15303 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameReceptor tyrosine-protein kinase erbB-4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ15303
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor tyrosine-protein kinase erbB-4
UniProt AccessionQ15303
Component TypeProtein
Sequence Length1308 aa

Receptor tyrosine-protein kinase erbB-4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Receptor tyrosine-protein kinase erbB-4, mapped to UniProt Q15303. Sequence length is 1308 aa.

Mapped IDQ15303
Review nameReceptor tyrosine-protein kinase erbB-4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Receptor tyrosine-protein kinase erbB-4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
6 linked drugs · 6 direct · 6 efficacy
Linked drugAC-480
Linked drugBMS-690514
Linked drugDACOMITINIB
Linked drugDACOMITINIB ANHYDROUS
Approved-linked Approved
non-small cell lung carcinoma
6 linked drugs · 6 direct · 6 efficacy
Linked drugAFATINIB DIMALEATE
Linked drugBMS-690514
Linked drugCANERTINIB DIHYDROCHLORIDE
Linked drugDACOMITINIB
Approved-linked Approved
breast cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugBMS-690514
Linked drugNERATINIB
Linked drugNERATINIB MALEATE
Approved-linked Approved
breast neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugCANERTINIB DIHYDROCHLORIDE
Linked drugNERATINIB
Linked drugNERATINIB MALEATE
Approved-linked Approved
breast carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugNERATINIB
Linked drugNERATINIB MALEATE
Late clinical Phase III
biliary tract neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugNERATINIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AC-480, BMS-690514, DACOMITINIB, DACOMITINIB ANHYDROUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

32
Approved
11
Phase III
17
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50367.0
KI688.0
KD104.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4646030 10.52 IC50 0.03 Preclinical
CHEMBL1873475 10.0 IC50 0.1 Approved
CHEMBL4642574 9.72 IC50 0.19 Preclinical
CHEMBL4517633 9.35 IC50 0.45 Preclinical
CHEMBL203644 9.3 IC50 0.5 Preclinical
CHEMBL4211949 9.22 IC50 0.6 Preclinical
CHEMBL437890 9.1 IC50 0.8 Preclinical
CHEMBL1947204 9.1 IC50 0.8 Clinical
CHEMBL1873475 9.04 Kd 0.91 Approved
CHEMBL203661 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
60
5.5
72
6.0
45
6.5
62
7.0
50
7.5
60
8.0
25
8.5
12
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIRABRUTINIB
CHEMBL4071161
Approved 2020
Properties Compare Identifier
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
Properties Compare Identifier
DACOMITINIB
CHEMBL2105719
Approved 2018
Properties Compare Identifier
DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
Properties Compare Identifier
NERATINIB
CHEMBL180022
Approved 2017
Properties Compare Identifier
ACALABRUTINIB
CHEMBL3707348
Approved 2017
Properties Compare Identifier
BRIGATINIB
CHEMBL3545311
Approved 2017
Properties Compare Identifier
IBRUTINIB
CHEMBL1873475
Approved 2013
Properties Compare Identifier
AFATINIB
CHEMBL1173655
Approved 2013
Properties Compare Identifier
AFATINIB DIMALEATE
CHEMBL2105712
Approved 2013
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
VANDETANIB
CHEMBL24828
Approved 2011
Properties Compare Identifier
LAPATINIB
CHEMBL554
Approved 2007
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
ERLOTINIB
CHEMBL553
Approved 2004
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
Assay Landscape

Assay Landscape

532
Total Assays
266
Tested Compounds
3
Assay Types
Binding — 520 assays, 266 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 409 131 7.2
assay format 64 43 7.5
cell-based format 47 92 7.1
ADME — 8 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 1 7.4
single protein format 3 2 9.2
cell-based format 2 0 —
Functional — 4 assays, 92 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 88 6.3
cell-based format 2 4 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine